FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387433040> ?p ?o ?g. }

• W4387433040 abstract "Real-life comparisons of dolutegravir/rilpivirine (DTG/RPV) and DTG/lamivudine (3TC) regimens in people living with human immunodeficiency virus (PLWHIV) who switched from a standard three-drug regimen based on nonnucleoside reverse transcriptase inhibitors (NNRTIs) are missing. This study aimed to compare DTG/3TC and DTG/RPV in virologically suppressed patients (HIV-RNA < 50 copies/mL) coming from any NNRTI-based regimen in terms of discontinuation due to virologic failure (VF) discontinuation rates due to all causes, and adverse events. As a secondary outcome, we evaluated the difference in creatinine, total cholesterol, CD4, and triglycerides from baseline to weeks 48 after the switch. Of the 415 PLWHs included in the study, 278 (66.9%) switched to DTG/3TC, and 137 (33.1%) switched to DTG/RPV. Overall, 48 PLWHs (11.6%) discontinued the treatment:38 with DTG/3TC and 10 with DTG/RPV with similar discontinuation rates: 5.01 × 100 py (95% confidence interval [CI] 3.64-6.94) and 4.66 × 100 py (95% CI 2.51-8.67), respectively. The most common reason for discontinuation was toxicity (26 patients, 22/278 [7.9%] in the DTG/3TC group and 4/137 [2.9%] in the DTG/RPV group), mainly neurologic toxicity (never above grade 2). We found no differences in discontinuation rates due to treatment adverse events. Two study participants experienced virological failure in the DTG/3TC arm. We observed no significant difference in CD4 cell counts, lipid parameters, or renal function between the two groups at 48 weeks. This study demonstrated that, in clinical practice, a two-drug regimen with DTG/3TC or DTG/RPV is characterized by a low discontinuation rate and VF in virologically suppressed PLWHs switched from an NNRTI-based three antiretroviral drugs regimen." @default.
• W4387433040 created "2023-10-09" @default.
• W4387433040 creator A5008126184 @default.
• W4387433040 creator A5009952922 @default.
• W4387433040 creator A5011090514 @default.
• W4387433040 creator A5014000382 @default.
• W4387433040 creator A5015006843 @default.
• W4387433040 creator A5016247442 @default.
• W4387433040 creator A5016846891 @default.
• W4387433040 creator A5019804232 @default.
• W4387433040 creator A5041785868 @default.
• W4387433040 creator A5048127995 @default.
• W4387433040 creator A5051949885 @default.
• W4387433040 creator A5061140872 @default.
• W4387433040 creator A5075421970 @default.
• W4387433040 creator A5078656388 @default.
• W4387433040 creator A5082122622 @default.
• W4387433040 date "2023-10-01" @default.
• W4387433040 modified "2023-10-12" @default.
• W4387433040 title "Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study" @default.
• W4387433040 cites W1536774371 @default.
• W4387433040 cites W1573555503 @default.
• W4387433040 cites W2518975640 @default.
• W4387433040 cites W2554692247 @default.
• W4387433040 cites W2556153964 @default.
• W4387433040 cites W2595476392 @default.
• W4387433040 cites W2728117782 @default.
• W4387433040 cites W2781681713 @default.
• W4387433040 cites W2789365482 @default.
• W4387433040 cites W2791139413 @default.
• W4387433040 cites W2793832384 @default.
• W4387433040 cites W2895195198 @default.
• W4387433040 cites W2959367164 @default.
• W4387433040 cites W2996250544 @default.
• W4387433040 cites W2998855521 @default.
• W4387433040 cites W3000709627 @default.
• W4387433040 cites W3099562535 @default.
• W4387433040 cites W3207788568 @default.
• W4387433040 cites W4214495631 @default.
• W4387433040 cites W4225822799 @default.
• W4387433040 cites W4280560544 @default.
• W4387433040 cites W4307092405 @default.
• W4387433040 doi "https://doi.org/10.1002/jmv.29149" @default.
• W4387433040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37805832" @default.
• W4387433040 hasPublicationYear "2023" @default.
• W4387433040 type Work @default.
• W4387433040 citedByCount "0" @default.
• W4387433040 crossrefType "journal-article" @default.
• W4387433040 hasAuthorship W4387433040A5008126184 @default.
• W4387433040 hasAuthorship W4387433040A5009952922 @default.
• W4387433040 hasAuthorship W4387433040A5011090514 @default.
• W4387433040 hasAuthorship W4387433040A5014000382 @default.
• W4387433040 hasAuthorship W4387433040A5015006843 @default.
• W4387433040 hasAuthorship W4387433040A5016247442 @default.
• W4387433040 hasAuthorship W4387433040A5016846891 @default.
• W4387433040 hasAuthorship W4387433040A5019804232 @default.
• W4387433040 hasAuthorship W4387433040A5041785868 @default.
• W4387433040 hasAuthorship W4387433040A5048127995 @default.
• W4387433040 hasAuthorship W4387433040A5051949885 @default.
• W4387433040 hasAuthorship W4387433040A5061140872 @default.
• W4387433040 hasAuthorship W4387433040A5075421970 @default.
• W4387433040 hasAuthorship W4387433040A5078656388 @default.
• W4387433040 hasAuthorship W4387433040A5082122622 @default.
• W4387433040 hasConcept C126322002 @default.
• W4387433040 hasConcept C142462285 @default.
• W4387433040 hasConcept C159047783 @default.
• W4387433040 hasConcept C197934379 @default.
• W4387433040 hasConcept C2522874641 @default.
• W4387433040 hasConcept C2777351918 @default.
• W4387433040 hasConcept C2777869810 @default.
• W4387433040 hasConcept C2778375690 @default.
• W4387433040 hasConcept C2778715236 @default.
• W4387433040 hasConcept C2778723075 @default.
• W4387433040 hasConcept C2779502633 @default.
• W4387433040 hasConcept C2780593183 @default.
• W4387433040 hasConcept C2781413609 @default.
• W4387433040 hasConcept C2993143319 @default.
• W4387433040 hasConcept C3013748606 @default.
• W4387433040 hasConcept C71924100 @default.
• W4387433040 hasConcept C90924648 @default.
• W4387433040 hasConcept C98274493 @default.
• W4387433040 hasConceptScore W4387433040C126322002 @default.
• W4387433040 hasConceptScore W4387433040C142462285 @default.
• W4387433040 hasConceptScore W4387433040C159047783 @default.
• W4387433040 hasConceptScore W4387433040C197934379 @default.
• W4387433040 hasConceptScore W4387433040C2522874641 @default.
• W4387433040 hasConceptScore W4387433040C2777351918 @default.
• W4387433040 hasConceptScore W4387433040C2777869810 @default.
• W4387433040 hasConceptScore W4387433040C2778375690 @default.
• W4387433040 hasConceptScore W4387433040C2778715236 @default.
• W4387433040 hasConceptScore W4387433040C2778723075 @default.
• W4387433040 hasConceptScore W4387433040C2779502633 @default.
• W4387433040 hasConceptScore W4387433040C2780593183 @default.
• W4387433040 hasConceptScore W4387433040C2781413609 @default.
• W4387433040 hasConceptScore W4387433040C2993143319 @default.
• W4387433040 hasConceptScore W4387433040C3013748606 @default.
• W4387433040 hasConceptScore W4387433040C71924100 @default.
• W4387433040 hasConceptScore W4387433040C90924648 @default.
• W4387433040 hasConceptScore W4387433040C98274493 @default.
• W4387433040 hasIssue "10" @default.

• next